Charles River Laboratories: Underperforming the Healthcare Sector?

Wednesday, Mar 25, 2026 5:24 am ET1min read
CRL--

Charles River Laboratories International (CRL) stock has underperformed the healthcare sector, with a 31% decline from its 52-week high and a 22.1% drop over the past three months. Despite better-than-expected Q4 results and a consensus rating of "Moderate Buy," analysts remain cautious about CRL's prospects. The stock's recent underperformance and bearish trend, trading below its 200-day moving average, suggests a bearish outlook.

Charles River Laboratories: Underperforming the Healthcare Sector?

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet